Clinical Development of Bispecific Antibodies: Review, Advances, and Challenges in Hematological Malignancies
A review catalogues approved and experimental bispecific antibodies for blood cancers, documenting pipeline innovation.
This J&J Medical Affairs-authored review chapter synthesizes the approved and advanced investigational bispecific antibodies in hematological malignancies, providing a current landscape of regulatory-approved agents and pivotal clinical trial results. It is a useful reference document for the downstream pipeline's treatment innovation tracker, though as a book chapter from an industry author it provides no new primary data.
What the study was
- Study design
- Narrative/educational review (book chapter)
- Population
- Patients with hematological malignancies receiving approved bispecific antibodies
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Methods in Molecular Biology
Why it surfaced
Current landscape review of approved bsAbs in hematologic malignancies by J&J Medical Affairs author. Useful pipeline reference but provides no new primary clinical evidence. Methods Mol Biol 2997 published multiple bsAb chapters in this window.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.